NCT06095167

Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC

Name: Clinical Trial NCT06095167
Creator: Fujian Cancer Hospital
Keywords: Nasopharyngeal Carcinoma, without concurrent cisplatin chemotherapy, Phase 3, drug, clinical trial, China

Prospective Randomized Trial Comparing Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa Nasopharyngeal Carcinoma

Fujian Cancer Hospital·Phase 3·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Nasopharyngeal Carcinoma
Drug/Device/Intervention: without concurrent cisplatin chemotherapy
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Fujian Cancer Hospital
Location: Fuzhou, China

Timeline & enrollment

Phase: Phase 3
Start date: Jan 01, 2024
End date: Jan 01, 2028
Enrollment: 476 participants

Primary outcome

Failure-free survival

Summary

The purpose of this study is to compare induction chemotherapy (gemcitabine+cisplatin) plus immunotherapy with concurrent chemoradiotherapy (CCRT) or RT alone in patients with stage III-IVa nasopharyngeal carcinoma(NPC), in order to confirm the value of Immunotherapy and concurrent chemotherapy in NPC patients.

ICD-10 classifications

Malignant neoplasm of nasopharynxMalignant neoplasm: Nasopharynx, unspecifiedMalignant neoplasm: Overlapping lesion of nasopharynxBenign neoplasm: NasopharynxMalignant neoplasm: Posterior wall of nasopharynx

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06095167
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06095167 through Pure Global AI's free database. This Phase 3 trial is sponsored by Fujian Cancer Hospital and is currently Not yet recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 476 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.